Zhaomin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhaomin Xu has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Thomas Aquina
Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, United States
35 shared publications - Fergal J. Fleming
Department of Surgery, University of Rochester Medical Center, Rochester, New York
31 shared publications - Adan Z. Becerra
University of Rochester Medical Center, Rochester, NY
21 shared publications John R. Monson
Department of Surgery, Center for Colon and Rectal Surgery, Florida Hospital Medical Group, Orlando, Florida
17 shared publicationsBradley J. Hensley
Department of Surgery, Surgical Health Outcomes and Research Enterprise (SHORE), University of Rochester Medical Center, Rochester, NY
14 shared publicationsFrancis P. Boscoe
New York State Cancer Registry, New York State Department of Health, Albany, NY, USA
14 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 337
Multimodal deep learning for objective skill assessment in robot-assisted vesico-urethral anastomosis
This study aimed to classify robot-assisted surgery (RAS) skill levels (inexperienced, competent, and experienced) during performance of vesico-urethral anastomosis (VUA) using multimodal physiological signals. We trained Convolutional Neural Networks (CNNs) and Long Short-Term Memory (LSTM) models on data collected from 23 RAS (RAS trainees and experienced surgeons) performing two VUAs on animal tissue. The dataset included 116-channel electroencephalogram (EEG) and 20 eye-tracking signals recorded during two VUA subtasks: (1) needle grasping, positioning, and entry; and (2) needle driving with wrist rotation and suture pull-out. Skill levels were rated by three raters using the Robotic Anastomosis Competency Evaluation (RACE) tool. Hyperparameters of the models were tuned using grid search with group 4-fold cross-validation on 16 participants and final model performance was evaluated on data from 7 unseen (held-out test) participants, repeated over 10 iterations. Weighted F-scores for classifying skill level using EEG and eye-tracking data were 0.84 for subtask 1 and 0.89 for subtask 2. Using paired t-tests, high-density EEG (116 channels) significantly outperformed low-density EEG (32 channels) for subtask 1 ( p = 0.001), with no difference for subtask 2 ( p = 0.15). Adding eye-tracking data significantly improved classification for subtask 2 ( p = 0.001), but not for subtask 1 ( p = 0.5). Multimodal deep learning using EEG and eye-tracking data enabled objective classification of surgical skills during VUA. The benefits of high-density EEG and multimodal integration were task-dependent, underscoring the need to tailor assessment tools to the cognitive and sensorimotor demands of specific surgical subtasks.
- 10 March 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 337
Open AccessMultimodal deep learning for objective skill assessment in robot-assisted vesico-urethral anastomosis
This study aimed to classify robot-assisted surgery (RAS) skill levels (inexperienced, competent, and experienced) during performance of vesico-urethral anastomosis (VUA) using multimodal physiological signals. We trained Convolutional Neural Networks (CNNs) and Long Short-Term Memory (LSTM) models on data collected from 23 RAS (RAS trainees and experienced surgeons) performing two VUAs on animal tissue. The dataset included 116-channel electroencephalogram (EEG) and 20 eye-tracking signals recorded during two VUA subtasks: (1) needle grasping, positioning, and entry; and (2) needle driving with wrist rotation and suture pull-out. Skill levels were rated by three raters using the Robotic Anastomosis Competency Evaluation (RACE) tool. Hyperparameters of the models were tuned using grid search with group 4-fold cross-validation on 16 participants and final model performance was evaluated on data from 7 unseen (held-out test) participants, repeated over 10 iterations. Weighted F-scores for classifying skill level using EEG and eye-tracking data were 0.84 for subtask 1 and 0.89 for subtask 2. Using paired t-tests, high-density EEG (116 channels) significantly outperformed low-density EEG (32 channels) for subtask 1 ( p = 0.001), with no difference for subtask 2 ( p = 0.15). Adding eye-tracking data significantly improved classification for subtask 2 ( p = 0.001), but not for subtask 1 ( p = 0.5). Multimodal deep learning using EEG and eye-tracking data enabled objective classification of surgical skills during VUA. The benefits of high-density EEG and multimodal integration were task-dependent, underscoring the need to tailor assessment tools to the cognitive and sensorimotor demands of specific surgical subtasks.
- Open Access
- 7 January 2026
- Published by Georg Thieme Verlag KG in Clinics in Colon and Rectal Surgery
Assessment Following Total Neoadjuvant Therapy for Rectal Cancer
Over the past decade, total neoadjuvant therapy (TNT) has become increasingly accepted and adopted as the initial treatment for locally advanced rectal cancer. Following TNT, treatment response is assessed using three main modalities: clinical exam, endoscopy, and imaging. In this article, we summarize the known advantages, disadvantages, and controversies associated with each method of assessment.
- 7 January 2026
- Published by Georg Thieme Verlag KG in Clinics in Colon and Rectal Surgery
Open AccessAssessment Following Total Neoadjuvant Therapy for Rectal Cancer
Over the past decade, total neoadjuvant therapy (TNT) has become increasingly accepted and adopted as the initial treatment for locally advanced rectal cancer. Following TNT, treatment response is assessed using three main modalities: clinical exam, endoscopy, and imaging. In this article, we summarize the known advantages, disadvantages, and controversies associated with each method of assessment.
- 23 June 2025
- Published by Georg Thieme Verlag KG in Clinics in Colon and Rectal Surgery
- Vol. 39 (02) , 117-121
Anal Dysplasia: Epidemiology, Risk Factors, and Progression to Malignancy
This review aims to address the framework for classification of anal dysplasia, immunogenic and behavioral risk factors for development of disease, the progression to anal cancer, and key intervention points to guide contemporary practice. Although anal cancer is rare, its rising incidence and disproportionate impact on racial minorities, immunocompromised individuals, and older adults require attention to combat high disease burden within these communities. Concentrated efforts with targeted resource allocation are required to address this rising disease incidence, following new screening guidelines developed to identify groups that are considered high-risk for anal dysplasia and the development of anal squamous cell carcinoma.
- 23 June 2025
- Published by Georg Thieme Verlag KG in Clinics in Colon and Rectal Surgery
- Vol. 39 (02) , 117-121
Anal Dysplasia: Epidemiology, Risk Factors, and Progression to Malignancy
This review aims to address the framework for classification of anal dysplasia, immunogenic and behavioral risk factors for development of disease, the progression to anal cancer, and key intervention points to guide contemporary practice. Although anal cancer is rare, its rising incidence and disproportionate impact on racial minorities, immunocompromised individuals, and older adults require attention to combat high disease burden within these communities. Concentrated efforts with targeted resource allocation are required to address this rising disease incidence, following new screening guidelines developed to identify groups that are considered high-risk for anal dysplasia and the development of anal squamous cell carcinoma.
- 14 October 2022
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 66 (7) , 1022-1028
Impact of Total Neoadjuvant Therapy on Postoperative Outcomes After Proctectomy for Rectal Cancer
BACKGROUND: Total neoadjuvant therapy is an alternative to neoadjuvant chemoradiation alone for rectal cancer and has the benefits of more completion of planned therapy, increased downstaging, earlier treatment of micrometastases, and assessment of chemosensitivity; however, it may increase surgical complications, especially with increased radiation-to-surgery interval. OBJECTIVE: The study aimed to determine the impact of total neoadjuvant therapy on postoperative complications compared with neoadjuvant chemoradiation alone. DESIGN: Retrospective cohort study. SETTINGS: Single tertiary referral center. PATIENTS: The patient included was a stage II/III rectal cancer patient who underwent total neoadjuvant therapy or long-course neoadjuvant chemoradiation followed by surgical resection from 2018–2020. MAIN OUTCOME MEASURES: The main outcome measures included severe postoperative complications (Clavien-Dindo grade ≥3). RESULTS: Of 181 patients, 86 (47.5%) underwent total neoadjuvant therapy and 95 (52.5%) underwent neoadjuvant chemoradiation. There was no difference in severe postoperative complications or any complications. There was also no difference in the rate of complete total mesorectal excision or negative circumferential margin. Total neoadjuvant therapy had a mean operative time of 355.5 minutes and estimated blood loss of 263.6 mL compared with 326.7 minutes and 297.5 mL in the neoadjuvant chemoradiation group. Total neoadjuvant therapy patients had a lower mean lymph node yield than neoadjuvant chemoradiation patients. On multivariable analysis, total neoadjuvant therapy was associated with increased operative time (OR, 1.19; p < 0.001) and estimated blood loss (OR, 1.22; p < 0.001) and decreased lymph node yield (OR, 0.67; p < 0.001). There was no difference in severe complications or any complications. LIMITATIONS: Selection bias uncontrolled by modeling. CONCLUSIONS: We found no difference in risk of postoperative complications between patients who received total neoadjuvant therapy vs neoadjuvant chemoradiation. Total neoadjuvant therapy patients had longer operations and greater estimated blood loss. This may be a reflection of increased operative difficulty because of increased radiation-to-surgery interval and/or the effects of chemotherapy; however, the absolute differences were small and, therefore, should be interpreted cautiously. See Video Abstract at http://links.lww.com/DCR/C44. IMPACTO DE LA TERAPIA NEOADYUVANTE TOTAL EN LOS RESULTADOS POSOPERATORIOS DESPUÉS DE UNA PROCTECTOMÍA POR CÁNCER DE RECTO: ANTECEDENTES: La terapia neoadyuvante total es una alternativa a la quimiorradiación neoadyuvante sola para el cáncer de recto y tiene los beneficios de una mayor finalización de la terapia planificada, mayor reducción del estadiage, tratamiento más temprano de las micrometástasis y evaluación de la quimiosensibilidad; sin embargo, puede aumentar las complicaciones quirúrgicas, especialmente con un mayor intervalo entre la radiación y la cirugía. OBJETIVO: Determinar el impacto de la terapia neoadyuvante total sobre las complicaciones posoperatorias en comparación con la quimiorradiación neoadyuvante sola. DISEÑO: Estudio de cohorte retrospectivo. ENTORNO CLINICO: Centro único de referencia terciario. PACIENTES: Paciente con cáncer de recto en estadio II/III que se sometieron a terapia neoadyuvante total o quimiorradiación neoadyuvante de larga duración seguida de resección quirúrgica entre 2018 y 2020. PRINCIPALES MEDIDAS DE RESULTADO: Complicaciones postoperatorias graves (grado de Clavien-Dindo ≥3). RESULTADOS: De 181 pacientes, 86 (47,5%) se sometieron a terapia neoadyuvante total y 95 (52,5%) se sometieron a quimiorradioterapia neoadyuvante. No hubo diferencia en las complicaciones postoperatorias graves o cualquier otra complicación. Tampoco hubo diferencia en la tasa de escisión mesorrectal total completa o margen circunferencial negativo. La terapia neoadyuvante total tuvo un tiempo operatorio promedio de 355,5 minutos y una pérdida de sangre estimada de 263,6 ml en comparación con 326,7 minutos y 297,5 ml en el grupo de quimiorradiación neoadyuvante. Los pacientes con terapia neoadyuvante total tuvieron una media de ganglios linfáticos más bajo en comparación con los pacientes con quimiorradioterapia neoadyuvante. En el análisis multivariable, la terapia neoadyuvante total se asoció con un mayor tiempo operatorio (OR = 1,19, p < 0,001) y pérdida de sangre estimada (OR = 1,22, p < 0,001) y menor cantidad los ganglios linfáticos (OR = 0,67, p < 0,001). No hubo diferencia en las complicaciones graves o cualquier complicación. LIMITACIONES: Sesgo de selección no controlado por modelado. CONCLUSIONES: No encontramos diferencias en el riesgo de complicaciones postoperatorias entre los pacientes que recibieron terapia neoadyuvante total versus quimiorradiación neoadyuvante. Los pacientes con terapia neoadyuvante total tuvieron operaciones más prolongadas y una mayor pérdida de sangre estimada. Esto puede ser un reflejo de una mayor dificultad quirúrgica como resultado de un mayor intervalo entre la radiación y la cirugía y/o los efectos de la quimioterapia; sin embargo, las diferencias absolutas fueron pequeñas y, por lo tanto, deben interpretarse con cautela. Consulte Video Resumen en http://links.lww.com/DCR/C44. (Traducción— Dr. Francisco M. Abarca-Rendon)
- 14 October 2022
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 66 (7) , 1022-1028
Impact of Total Neoadjuvant Therapy on Postoperative Outcomes After Proctectomy for Rectal Cancer
BACKGROUND: Total neoadjuvant therapy is an alternative to neoadjuvant chemoradiation alone for rectal cancer and has the benefits of more completion of planned therapy, increased downstaging, earlier treatment of micrometastases, and assessment of chemosensitivity; however, it may increase surgical complications, especially with increased radiation-to-surgery interval. OBJECTIVE: The study aimed to determine the impact of total neoadjuvant therapy on postoperative complications compared with neoadjuvant chemoradiation alone. DESIGN: Retrospective cohort study. SETTINGS: Single tertiary referral center. PATIENTS: The patient included was a stage II/III rectal cancer patient who underwent total neoadjuvant therapy or long-course neoadjuvant chemoradiation followed by surgical resection from 2018–2020. MAIN OUTCOME MEASURES: The main outcome measures included severe postoperative complications (Clavien-Dindo grade ≥3). RESULTS: Of 181 patients, 86 (47.5%) underwent total neoadjuvant therapy and 95 (52.5%) underwent neoadjuvant chemoradiation. There was no difference in severe postoperative complications or any complications. There was also no difference in the rate of complete total mesorectal excision or negative circumferential margin. Total neoadjuvant therapy had a mean operative time of 355.5 minutes and estimated blood loss of 263.6 mL compared with 326.7 minutes and 297.5 mL in the neoadjuvant chemoradiation group. Total neoadjuvant therapy patients had a lower mean lymph node yield than neoadjuvant chemoradiation patients. On multivariable analysis, total neoadjuvant therapy was associated with increased operative time (OR, 1.19; p < 0.001) and estimated blood loss (OR, 1.22; p < 0.001) and decreased lymph node yield (OR, 0.67; p < 0.001). There was no difference in severe complications or any complications. LIMITATIONS: Selection bias uncontrolled by modeling. CONCLUSIONS: We found no difference in risk of postoperative complications between patients who received total neoadjuvant therapy vs neoadjuvant chemoradiation. Total neoadjuvant therapy patients had longer operations and greater estimated blood loss. This may be a reflection of increased operative difficulty because of increased radiation-to-surgery interval and/or the effects of chemotherapy; however, the absolute differences were small and, therefore, should be interpreted cautiously. See Video Abstract at http://links.lww.com/DCR/C44. IMPACTO DE LA TERAPIA NEOADYUVANTE TOTAL EN LOS RESULTADOS POSOPERATORIOS DESPUÉS DE UNA PROCTECTOMÍA POR CÁNCER DE RECTO: ANTECEDENTES: La terapia neoadyuvante total es una alternativa a la quimiorradiación neoadyuvante sola para el cáncer de recto y tiene los beneficios de una mayor finalización de la terapia planificada, mayor reducción del estadiage, tratamiento más temprano de las micrometástasis y evaluación de la quimiosensibilidad; sin embargo, puede aumentar las complicaciones quirúrgicas, especialmente con un mayor intervalo entre la radiación y la cirugía. OBJETIVO: Determinar el impacto de la terapia neoadyuvante total sobre las complicaciones posoperatorias en comparación con la quimiorradiación neoadyuvante sola. DISEÑO: Estudio de cohorte retrospectivo. ENTORNO CLINICO: Centro único de referencia terciario. PACIENTES: Paciente con cáncer de recto en estadio II/III que se sometieron a terapia neoadyuvante total o quimiorradiación neoadyuvante de larga duración seguida de resección quirúrgica entre 2018 y 2020. PRINCIPALES MEDIDAS DE RESULTADO: Complicaciones postoperatorias graves (grado de Clavien-Dindo ≥3). RESULTADOS: De 181 pacientes, 86 (47,5%) se sometieron a terapia neoadyuvante total y 95 (52,5%) se sometieron a quimiorradioterapia neoadyuvante. No hubo diferencia en las complicaciones postoperatorias graves o cualquier otra complicación. Tampoco hubo diferencia en la tasa de escisión mesorrectal total completa o margen circunferencial negativo. La terapia neoadyuvante total tuvo un tiempo operatorio promedio de 355,5 minutos y una pérdida de sangre estimada de 263,6 ml en comparación con 326,7 minutos y 297,5 ml en el grupo de quimiorradiación neoadyuvante. Los pacientes con terapia neoadyuvante total tuvieron una media de ganglios linfáticos más bajo en comparación con los pacientes con quimiorradioterapia neoadyuvante. En el análisis multivariable, la terapia neoadyuvante total se asoció con un mayor tiempo operatorio (OR = 1,19, p < 0,001) y pérdida de sangre estimada (OR = 1,22, p < 0,001) y menor cantidad los ganglios linfáticos (OR = 0,67, p < 0,001). No hubo diferencia en las complicaciones graves o cualquier complicación. LIMITACIONES: Sesgo de selección no controlado por modelado. CONCLUSIONES: No encontramos diferencias en el riesgo de complicaciones postoperatorias entre los pacientes que recibieron terapia neoadyuvante total versus quimiorradiación neoadyuvante. Los pacientes con terapia neoadyuvante total tuvieron operaciones más prolongadas y una mayor pérdida de sangre estimada. Esto puede ser un reflejo de una mayor dificultad quirúrgica como resultado de un mayor intervalo entre la radiación y la cirugía y/o los efectos de la quimioterapia; sin embargo, las diferencias absolutas fueron pequeñas y, por lo tanto, deben interpretarse con cautela. Consulte Video Resumen en http://links.lww.com/DCR/C44. (Traducción— Dr. Francisco M. Abarca-Rendon)
- 11 August 2020
- Published by Springer Nature
- p. 95-99
Anorectal Abscess
- 24 July 2020
- Published by Wolters Kluwer Health in Journal of Pediatric Orthopaedics B
- Vol. 30 (5) , 488-493
What patient factors and Patient-Reported Outcomes Measurement Information System domains are associated with worse pain coping in pediatric orthopaedic patients in the United States?
We sought to better understand the relationship between Patient-Reported Outcomes Measurement Information System (PROMIS) mobility, pain interference (PI) and depressive symptoms scores, as well as determine what patient factors and PROMIS domains were associated with worse pain coping (PROMIS PI), in a pediatric orthopaedic population. Between 27 August 2015 and 30 April 2019, new pediatric orthopaedic patients 18 years or younger (or their guardians as a proxy) were asked to complete PROMIS mobility, PI and depressive symptoms domains at an academic medical center pediatric orthopaedic clinic. Pearson correlation coefficients (r) were calculated between each PROMIS domain. Linear multivariate regression analysis was used to determine patient characteristics and PROMIS domains associated with presenting PROMIS PI scores. There was a strong-moderate correlation between PROMIS mobility and PI (r = −0.66, P < 0.001), while the correlation between PROMIS mobility and depressive symptoms was moderate-poor (r = −0.38, P < 0.001). There was a moderate correlation between PROMIS depressive symptoms and PI (r = 0.54, P < 0.001). In multivariate linear regression analysis, female gender (β = 0.82, P < 0.001), self-reported black race (β = 0.94, P < 0.001), Medicaid insurance (β = 0.82, P < 0.001) and worsening depressive symptoms (β = 0.33, P < 0.001) were associated with worse pain coping mechanisms, while increasing mobility (β = −0.47, P < 0.001) was associated with better pain coping mechanisms. Poor mobility and worse depressive symptoms are associated with worse pain coping mechanisms. Additionally, Medicaid insurance status, black race and female gender are also associated with worse physical limitations secondary to pain.
- 24 July 2020
- Published by Wolters Kluwer Health in Journal of Pediatric Orthopaedics B
- Vol. 30 (5) , 488-493
What patient factors and Patient-Reported Outcomes Measurement Information System domains are associated with worse pain coping in pediatric orthopaedic patients in the United States?
We sought to better understand the relationship between Patient-Reported Outcomes Measurement Information System (PROMIS) mobility, pain interference (PI) and depressive symptoms scores, as well as determine what patient factors and PROMIS domains were associated with worse pain coping (PROMIS PI), in a pediatric orthopaedic population. Between 27 August 2015 and 30 April 2019, new pediatric orthopaedic patients 18 years or younger (or their guardians as a proxy) were asked to complete PROMIS mobility, PI and depressive symptoms domains at an academic medical center pediatric orthopaedic clinic. Pearson correlation coefficients (r) were calculated between each PROMIS domain. Linear multivariate regression analysis was used to determine patient characteristics and PROMIS domains associated with presenting PROMIS PI scores. There was a strong-moderate correlation between PROMIS mobility and PI (r = −0.66, P < 0.001), while the correlation between PROMIS mobility and depressive symptoms was moderate-poor (r = −0.38, P < 0.001). There was a moderate correlation between PROMIS depressive symptoms and PI (r = 0.54, P < 0.001). In multivariate linear regression analysis, female gender (β = 0.82, P < 0.001), self-reported black race (β = 0.94, P < 0.001), Medicaid insurance (β = 0.82, P < 0.001) and worsening depressive symptoms (β = 0.33, P < 0.001) were associated with worse pain coping mechanisms, while increasing mobility (β = −0.47, P < 0.001) was associated with better pain coping mechanisms. Poor mobility and worse depressive symptoms are associated with worse pain coping mechanisms. Additionally, Medicaid insurance status, black race and female gender are also associated with worse physical limitations secondary to pain.
- 16 June 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 255, 652
Response Regarding: Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer
- 16 June 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 255, 652
Response Regarding: Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer
- 6 May 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (11) , 4093-4106
Variation in Adequate Lymph Node Yield for Gastric, Lung, and Bladder Cancer: Attributable to the Surgeon, Pathologist, or Hospital?
The Commission on Cancer recently released quality-of-care measures regarding adequate lymphadenectomy for colon, gastric, lung, and bladder cancer. There
- 6 May 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (11) , 4093-4106
Variation in Adequate Lymph Node Yield for Gastric, Lung, and Bladder Cancer: Attributable to the Surgeon, Pathologist, or Hospital?
The Commission on Cancer recently released quality-of-care measures regarding adequate lymphadenectomy for colon, gastric, lung, and bladder cancer. There
- Open Access
- 29 April 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 655
Quality Assurance, Metrics, and Improving Standards in Rectal Cancer Surgery in the United States
Rectal cancer surgery has seen significant improvement in recent years. This has been possible in part due to focus on surgeon education and training, specific surgical quality metrics, and longitudinal tracking of data through the use of registries. In countries that have implemented such efforts, data has shown significant improvement in outcomes. However, there continues to be significant variation in rectal cancer outcomes and practices worldwide. Just within the United States, county level mortality rates from rectal cancer range from 8–15 per 100,000 to 38–59 per 100,000. In order to continue to improve rectal cancer patient outcomes, there needs to be evidence based guidelines and standards centered around the framework of structure, process, and outcomes. In addition, there must be a feedback system by which programs can continually assess their performance. Obtaining evidence for specific standards and measures can be challenging and requires analyzing available data and literature, some of which may be conflicting. This article evaluates the evolution of metrics and standards used for quality improvement in rectal cancer and ongoing efforts to further improve patient outcomes.
- 29 April 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 655
Open AccessQuality Assurance, Metrics, and Improving Standards in Rectal Cancer Surgery in the United States
Rectal cancer surgery has seen significant improvement in recent years. This has been possible in part due to focus on surgeon education and training, specific surgical quality metrics, and longitudinal tracking of data through the use of registries. In countries that have implemented such efforts, data has shown significant improvement in outcomes. However, there continues to be significant variation in rectal cancer outcomes and practices worldwide. Just within the United States, county level mortality rates from rectal cancer range from 8–15 per 100,000 to 38–59 per 100,000. In order to continue to improve rectal cancer patient outcomes, there needs to be evidence based guidelines and standards centered around the framework of structure, process, and outcomes. In addition, there must be a feedback system by which programs can continually assess their performance. Obtaining evidence for specific standards and measures can be challenging and requires analyzing available data and literature, some of which may be conflicting. This article evaluates the evolution of metrics and standards used for quality improvement in rectal cancer and ongoing efforts to further improve patient outcomes.
- 1 March 2020
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 63 (3) , 319-325
Centralizing Rectal Cancer Surgery: What Is the Impact of Travel on Patients?
BACKGROUND: It is unclear what impact centralizing rectal cancer surgery may have on travel burden for patients. OBJECTIVE: This study aimed to determine the impact of centralizing rectal cancer surgery to high-volume centers on patient travel distance. DESIGN: This is a population-based study. SETTINGS: The New York State Cancer Registry and Statewide Planning and Research Cooperative System were queried for patients with rectal cancer undergoing proctectomy. PATIENTS: Patients with stage I to III rectal cancer who underwent surgical resection between 2004 and 2014 were included. MAIN OUTCOME MEASURES: The outcome of interest was travel distance calculated as the straight-line distance between the centroid of the patient residence zip code and the hospital zip code. Mean distance was compared by using the Student t test. RESULTS: A total of 5860 patients met inclusion criteria. The total number of hospitals performing proctectomies for rectal cancer decreased between 2004 and 2014. The average number of proctectomies performed at high-volume centers (20+ resections/year) increased from 16.6 to 24.4 during this time. The average number of miles traveled by patients was 12.1 miles in 2004, and this increased to 15.4 in 2014. If proctectomies were centralized to high-volume centers, there would be 11 facilities. The mean distance traveled would be 24.5 miles. LIMITATIONS: This study is subject to the limitations of an administrative data set. There are no patient preference or referral data. CONCLUSIONS: The number of hospitals performing rectal cancer resections in New York State is decreasing and volume by center is increasing. There was a statistically significant difference in the mean distance traveled by patients over time. If rectal cancer resections were centralized to high-volume centers, the mean travel distance would increase by 9.5 miles. There would be a 321% increase in the number of patients having to travel 50+ miles for surgery. Any plan for centralization in New York State will require careful planning to avoid placing undue travel burden on patients. See Video Abstract at http://links.lww.com/DCR/B138. CENTRALIZACIÓN DE LA CIRUGÍA DE CÁNCER RECTAL: ¿CUÁL ES EL IMPACTO DEL VIAJE PARA LOS PACIENTES?: ANTECEDENTES: No está claro qué impacto puede tener la centralización de la cirugía de cáncer rectal en la carga de viaje para los pacientes. OBJETIVO: Determinar el impacto de centralizar la cirugía de cáncer rectal en centros de alto volumen sobre la distancia de viaje del paciente. DISEÑO: Este es un estudio basado en cohorte poblacional. ESCENARIO: El Registro de Cáncer del Estado de Nueva York y el Sistema Cooperativo de Planificación e Investigación Estatal fueron consultados para pacientes con cáncer rectal sometidos a proctectomía. PACIENTES: Pacientes con cáncer rectal en estadio I-III que se sometieron a resección quirúrgica entre 2004-2014. PRINCIPALES MEDIDAS DE RESULTADO: El resultado de interés fue la distancia de viaje calculada como la distancia en línea recta entre el centroide de la residencia del paciente y el código postal del hospital. La distancia media se comparó mediante la prueba t de Student. RESULTADOS: Un total de 5,860 pacientes cumplieron los criterios de inclusión. El número total de hospitales que realizaron proctectomías para cáncer rectal disminuyó entre 2004-2014. El número promedio de proctectomías realizadas en centros de alto volumen (más de 20 resecciones/año) aumentó de 16.6 a 24.4 durante este tiempo. El número promedio de millas recorridas por los pacientes fue de 12.1 millas en 2004 y esto aumentó a 15.4 en 2014. Si las proctectomías se centralizaran en centros de alto volumen, habría 11 instalaciones. La distancia media recorrida sería de 24.5 millas. LIMITACIONES: Limitaciones inherentes a un conjunto de datos administrativos. No existen datos sobre preferencia del paciente o sobre referencia de los mismos. CONCLUSIONES: El número de hospitales que realizan resecciones de cáncer rectal en Nueva York está disminuyendo y el volumen por centro está aumentando. Hubo una diferencia estadísticamente significativa en la distancia media recorrida por los pacientes a lo largo del tiempo. Si las resecciones por cáncer rectal se centralizaran en centros de gran volumen, la distancia media de viaje aumentaría 9.5 millas. Habría un aumento del 321% en el número de pacientes que tienen que viajar más de 50 millas para la cirugía. Cualquier plan de centralización en Nueva York requerirá una planificación cuidadosa para evitar imponer una carga de viaje excesiva a los pacientes. Consulte Video Resumen en http://links.lww.com/DCR/B138.
- 1 March 2020
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 63 (3) , 319-325
Centralizing Rectal Cancer Surgery: What Is the Impact of Travel on Patients?
BACKGROUND: It is unclear what impact centralizing rectal cancer surgery may have on travel burden for patients. OBJECTIVE: This study aimed to determine the impact of centralizing rectal cancer surgery to high-volume centers on patient travel distance. DESIGN: This is a population-based study. SETTINGS: The New York State Cancer Registry and Statewide Planning and Research Cooperative System were queried for patients with rectal cancer undergoing proctectomy. PATIENTS: Patients with stage I to III rectal cancer who underwent surgical resection between 2004 and 2014 were included. MAIN OUTCOME MEASURES: The outcome of interest was travel distance calculated as the straight-line distance between the centroid of the patient residence zip code and the hospital zip code. Mean distance was compared by using the Student t test. RESULTS: A total of 5860 patients met inclusion criteria. The total number of hospitals performing proctectomies for rectal cancer decreased between 2004 and 2014. The average number of proctectomies performed at high-volume centers (20+ resections/year) increased from 16.6 to 24.4 during this time. The average number of miles traveled by patients was 12.1 miles in 2004, and this increased to 15.4 in 2014. If proctectomies were centralized to high-volume centers, there would be 11 facilities. The mean distance traveled would be 24.5 miles. LIMITATIONS: This study is subject to the limitations of an administrative data set. There are no patient preference or referral data. CONCLUSIONS: The number of hospitals performing rectal cancer resections in New York State is decreasing and volume by center is increasing. There was a statistically significant difference in the mean distance traveled by patients over time. If rectal cancer resections were centralized to high-volume centers, the mean travel distance would increase by 9.5 miles. There would be a 321% increase in the number of patients having to travel 50+ miles for surgery. Any plan for centralization in New York State will require careful planning to avoid placing undue travel burden on patients. See Video Abstract at http://links.lww.com/DCR/B138. CENTRALIZACIÓN DE LA CIRUGÍA DE CÁNCER RECTAL: ¿CUÁL ES EL IMPACTO DEL VIAJE PARA LOS PACIENTES?: ANTECEDENTES: No está claro qué impacto puede tener la centralización de la cirugía de cáncer rectal en la carga de viaje para los pacientes. OBJETIVO: Determinar el impacto de centralizar la cirugía de cáncer rectal en centros de alto volumen sobre la distancia de viaje del paciente. DISEÑO: Este es un estudio basado en cohorte poblacional. ESCENARIO: El Registro de Cáncer del Estado de Nueva York y el Sistema Cooperativo de Planificación e Investigación Estatal fueron consultados para pacientes con cáncer rectal sometidos a proctectomía. PACIENTES: Pacientes con cáncer rectal en estadio I-III que se sometieron a resección quirúrgica entre 2004-2014. PRINCIPALES MEDIDAS DE RESULTADO: El resultado de interés fue la distancia de viaje calculada como la distancia en línea recta entre el centroide de la residencia del paciente y el código postal del hospital. La distancia media se comparó mediante la prueba t de Student. RESULTADOS: Un total de 5,860 pacientes cumplieron los criterios de inclusión. El número total de hospitales que realizaron proctectomías para cáncer rectal disminuyó entre 2004-2014. El número promedio de proctectomías realizadas en centros de alto volumen (más de 20 resecciones/año) aumentó de 16.6 a 24.4 durante este tiempo. El número promedio de millas recorridas por los pacientes fue de 12.1 millas en 2004 y esto aumentó a 15.4 en 2014. Si las proctectomías se centralizaran en centros de alto volumen, habría 11 instalaciones. La distancia media recorrida sería de 24.5 millas. LIMITACIONES: Limitaciones inherentes a un conjunto de datos administrativos. No existen datos sobre preferencia del paciente o sobre referencia de los mismos. CONCLUSIONES: El número de hospitales que realizan resecciones de cáncer rectal en Nueva York está disminuyendo y el volumen por centro está aumentando. Hubo una diferencia estadísticamente significativa en la distancia media recorrida por los pacientes a lo largo del tiempo. Si las resecciones por cáncer rectal se centralizaran en centros de gran volumen, la distancia media de viaje aumentaría 9.5 millas. Habría un aumento del 321% en el número de pacientes que tienen que viajar más de 50 millas para la cirugía. Cualquier plan de centralización en Nueva York requerirá una planificación cuidadosa para evitar imponer una carga de viaje excesiva a los pacientes. Consulte Video Resumen en http://links.lww.com/DCR/B138.